@article{920598a2c958435c910fcf3c2fe92335,
title = "EORTC-1203-GITCG - the {"}INNOVATION{"}-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group",
keywords = "Gastric cancer, Gastro-esophageal junction cancer, Perioperative chemotherapy, Trastuzumab, Pertuzumab, HER2, NEOADJUVANT CHEMOTHERAPY, BREAST-CANCER, OPEN-LABEL, CAPECITABINE, OXALIPLATIN, REGRESSION, DOCETAXEL, SURGERY",
author = "Wagner, {Anna Dorothea} and Heike Grabsch and Murielle Mauer and Sandrine Marreaud and Carmela Caballero and Peter Thuss-Patience and Lothar Mueller and Annelie Elme and Moehler, {Markus Hermann} and Uwe Martens and Yoon-Koo Kang and Rha, {Sun Young} and Annemieke Cats and Masanori Tokunaga and Florian Lordick",
year = "2019",
month = may,
day = "24",
doi = "10.1186/s12885-019-5675-4",
language = "English",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd",
}